In pediatric advanced airway management with Facilitated Laryngoscopy/Supraglottic airway, which induction agent is used with a maximum dose of 30 mg?

Study for the BSO Protocols Test. Master key concepts with flashcards and multiple choice questions, each with hints and explanations. Get ready for your exam!

Multiple Choice

In pediatric advanced airway management with Facilitated Laryngoscopy/Supraglottic airway, which induction agent is used with a maximum dose of 30 mg?

Explanation:
Etomidate is chosen here because it provides rapid, smooth induction with minimal impact on heart rate and blood pressure, which is especially important during pediatric airway management. The dosing is 0.3 mg/kg given IV or IO with a practical maximum of 30 mg, giving a quick onset for facilitating laryngoscopy or placing a supraglottic airway while keeping hemodynamics stable and allowing a brief window before any potential apnea or deeper sedation occurs. The other agents either carry a higher risk of hypotension (propofol), slower onset or greater respiratory depression (midazolam), or have different airway effects and dosing patterns (ketamine), making them less ideal for this specific scenario.

Etomidate is chosen here because it provides rapid, smooth induction with minimal impact on heart rate and blood pressure, which is especially important during pediatric airway management. The dosing is 0.3 mg/kg given IV or IO with a practical maximum of 30 mg, giving a quick onset for facilitating laryngoscopy or placing a supraglottic airway while keeping hemodynamics stable and allowing a brief window before any potential apnea or deeper sedation occurs. The other agents either carry a higher risk of hypotension (propofol), slower onset or greater respiratory depression (midazolam), or have different airway effects and dosing patterns (ketamine), making them less ideal for this specific scenario.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy